Advances in Lymphoma. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Ibrutinib Monotherapy. GS-9973 and Idelasib in Patients With R/R CLL. ABT-199 in Patients With R/R CLL/SLL. Hodgkin Lymphoma. ABVD With and Without Bleomycin and/or Dacarbazine. - PowerPoint PPT Presentation
Citation preview
Advances in Lymphoma
Chronic Lymphocytic Leukemia/Small Lymphocytic
Lymphoma
Ibrutinib Monotherapy
GS-9973 and Idelasib in Patients With R/R CLL
ABT-199 in Patients With R/R CLL/SLL
Hodgkin Lymphoma
ABVD With and Without Bleomycin and/or Dacarbazine
Brentuximab Vedotin Followed by ABVD in Patients With Untreated
NHL
Single-Agent Brentuximab Vedotin in R/R Hodgkin Lymphoma
Follicular Lymphoma
Prognostic Value of PET-CT After FL Therapy in FL
FOLL05, 5-Year Follow-up
Alliance/CALGB 50803Lenalidomide Plus Rituximab for Untreated
FL
ROMULUSPolatuzumab Vedotin or Pinatuzumab Vedotin
Plus Rituximab in Patients With R/R FL
Diffuse Large B-Cell Lymphoma
Two Different R-CHOP Variants
ABT-199 for DLBCL
Monitoring MRD Using Cellular and Acellular Blood DNA
Mantle Cell Lymphoma
R-CHOP vs VR-CAP for BMT-Ineligible Newly Diagnosed
Patients With MCL
Subcutaneous Bortezomib in Relapsed MCL
Safety of Ibrutinib in R/R MCL
T-Cell Lymphoma
Alisertib for PTCL
Response to Romidepsin by Number of Lines of Prior Therapies
in R/R PTCL
Topical SHP-141 for CTCL
Outcomes of Patients With PTCL From the BCCA Registry After